INVITED REVIEW

Tissue transglutaminase: a new target to reverse cancer drug resistance

Alfredo Budillon · Carmine Carbone · Elena Di Gennaro

Received: 5 July 2011 / Accepted: 18 November 2011 / Published online: 1 December 2011 © The Author(s) 2011. This article is published with open access at Springerlink.com

Abstract Cancer resistance mechanisms, which result from intrinsic genetic alterations of tumor cells or acquired genetic and epigenetic changes, limit the long-lasting benefits of anti-cancer treatments. Tissue transglutaminase (TG2) has emerged as a putative gene involved in tumor cell drug resistance and evasion of apoptosis. Although some reports have indicated that TG2 can suppress tumor growth and enhance the growth inhibitory effects of anti-tumor agents, several studies have presented both pro-survival and anti-apoptotic roles for TG2 in malignant cells. Increased TG2 expression has been found in several tumors, where it was considered a potential negative prognostic marker, and it is often associated with advanced stages of disease, metastatic spread and drug resistance. TG2 mediates drug resistance through the activation of survival pathways and the inhibition of apoptosis, but also by regulating extracellular matrix (ECM) formation, the epithelial-to-mesenchymal transition (EMT) or autophagy. Because TG2 knockdown or inhibition of TG2 enzymatic activity may reverse drug resistance and sensitize cancer cells to drug-induced apoptosis, many small molecules capable of blocking TG2 have recently been developed. Additional insight into the multifunctional nature of TG2 as well as translational studies concerning the correlation between TG2 expression, function or location and cancer behavior will aid in translating these findings into new therapeutic approaches for cancer patients.

Keywords Tissue transglutaminase · Cancer · Chemotherapy · Resistance

Introduction

Despite advances in our understanding of the molecular mechanisms of tumor development, prevention and treatment, the long-term survival for patients with recurrent/advanced disease remains low. Resistance to chemotherapy as well as the genetic heterogeneity of tumors is the leading causes of limited activity in anti-cancer strategies. Although higher response rates have been achieved using the latest poly-chemotherapy regimens and molecular targeted compounds, tumor resistance mechanisms resulting from intrinsic genetic alterations of tumor cells or acquired genetic and epigenetic changes limit the long-lasting benefits of anti-cancer treatments.

Tumor progression and metastasis requires cancer cells to circumvent stress conditions, such as hypoxia or lack of nutrients, and escape the immune system attack. This selective pressure facilitates metastatic potential by activating tumor survival mechanisms against the pro-apoptotic signals induced by physiological and pharmacological conditions. Indeed, metastatic tumors are highly resistant to chemotherapy drugs, and tumors resistant to chemotherapy show more aggressive metastatic phenotypes. Over the past 20 years, many genes that may be involved in the mechanisms of drug resistance have been identified. Among these, several studies have indicated tissue transglutaminase, also defined as transglutaminase 2 (TG2), as a putative gene involved in tumor drug resistance and evasion of apoptosis.

TG2 is a member of the larger family of transglutaminases and is a multi-domain, multifunctional enzyme.
that is ubiquitously expressed in mammalian tissues and involved in a variety of cellular processes. TG2 catalyzes Ca$^{2+}$-dependent post-translational protein modifications by inserting irreversible $\varepsilon$-(\textgamma-glutamyl)-lysine cross-links between polypeptide chains. TG2 is also known to have guanosine-5-triphosphate hydrolase, protein disulfide isomerase and protein kinase activities (Mehta et al. 2010; Park et al. 2010a). Although predominantly localized within the cytosol, nucleus and cellular membrane compartments, TG2 can also be secreted outside the cell. Consequently, TG2 has been associated with several biological functions including signal transduction, apoptosis, cell adhesion, cell migration and extracellular matrix (ECM) formation (Mehta et al. 2010; Park et al. 2010a).

TG2 has been described as a promoter or an antagonist of apoptosis depending on the relevant cellular context. Although some reports have indicated that TG2 can suppress tumor growth and contribute to the growth inhibitory effects of anti-tumor agents, several studies support a pro-survival and anti-apoptotic role for TG2 in malignant cells.

TG2 exerts its anti-apoptotic effects through different mechanisms involving both its transamidation and GTP-binding activities. For instance, TG2-induced protein cross-linking protects tumor cells from caspase cleavage and promotes NFκB-dependent cell survival (Kim et al. 2006; Mann et al. 2006; Yamaguchi and Wang 2006; Verma and Mehta 2007; Jang et al. 2010a). Moreover, TG2-mediated transamidation of RB in the nucleus protects this oncogenic protein from degradation, thereby promoting survival (Boehm et al. 2002). Furthermore, the association of TG2 with some members of the integrin family promotes the anchoring of cells to the ECM and activates cell survival pathways (Akimov et al. 2000; Herman et al. 2006; Mangala et al. 2007).

Some of these mechanisms will be further described in the following sections. In detail, we will provide potential mechanistic explanations for the association between TG2 induction and the emergence of cancer drug resistance and suggest how TG2 targeting may potentiate anti-cancer strategies.

**TG2 and cancer aggressiveness**

TG2 overexpression has been observed in pancreatic (Iacobuzio-Donahue et al. 2003), breast (Grigoriev et al. 2001; Mehta et al. 2004), colon (Miyoshi et al. 2010), ovarian (Satpathy et al. 2007) and non-small cell lung cancers (NSCLC) (Martinet et al. 2003), as well as in glioblastoma (Zhang et al. 2003) and melanoma (Fok et al. 2006). Increased TG2 expression has been considered a potential negative prognostic marker and is often associated with advanced stages of disease, metastatic spread and drug resistance (Zhang et al. 2003; Mehta et al. 2004, 2006; Fok et al. 2006; Herman et al. 2006).

Cell invasion is critical to cancer metastasis and involves a phenotypic switch and an extensive remodeling of the ECM by matrix metalloproteinases (MMPs). The importance of TG2 in ECM deposition and stabilization is now well established and supports studies that have demonstrated the involvement of TG2 in wound healing and inflammation (Chau et al. 2005; Collighan and Griffin 2009; Fisher et al. 2009; Mehta et al. 2010). Notably, chronic inflammation can lead to cancer development. TG2 can bind the gelatin-binding domain of fibronectin with high affinity through its N-terminal $\beta$-sandwich domain and enhance the association of fibronectin and integrins on the cell surface. In this way, TG2 can influence several aspects of cancer cell behavior, including motility, invasion, growth, and survival (Akimov et al. 2000; Chau et al. 2005; Mangala et al. 2007; Collighan and Griffin 2009; Fisher et al. 2009; Mehta et al. 2010).

TG2 can act either by direct cross-linking or by its GTP-binding site that mediates signal transduction via phospholipase C, focal adhesion kinase and PI3K activation (Mehta et al. 2010).

Recently, it has been demonstrated that aberrant expression of TG2 is sufficient for inducing the transdifferentiation of mammary epithelial cells into mesenchymal cells, a process known as the epithelial-to-mesenchymal transition (EMT), which is required during embryonic development and is associated with increased tumor aggressiveness and metastatic potential (Kumar et al. 2010). TG2-induced EMT confers invasiveness, drug resistance and a tumorigenic phenotype, and some authors have suggested that this finding establishes a strong link between TG2 expression and the progression of metastatic breast disease (Kumar et al. 2010). Similarly, it has been demonstrated that ovarian cancer cells expressing TG2 adopt a mesenchymal phenotype characterized by the loss of epithelial markers and an increase in invasive behavior. This mechanism seems to be mediated by activation of the NFκB complex via TG2. Moreover, the TG2-dependent induction of EMT in an orthotopic xenograft ovarian model led to increased tumor formation, peritoneal metastases and malignant ascites (Shao et al. 2009).

Finally, a recent study provided first-time evidence demonstrating that sustained expression of TG2 conferred stem cell-like properties in non-transformed and transformed mammary epithelial cells, while downregulation of TG2 attenuated stem cell properties in both populations. Taken together, these results suggest a new function for TG2 and reveal a novel mechanism responsible for promoting stem cell characteristics in adult mammary epithelial cells (Kumar et al. 2011).
TG2 and drug resistance

As reported above, high levels of TG2 expression were observed in drug-resistant cancer cells. Interestingly, TG2 knockdown or TG2 enzymatic inhibitors may reverse drug resistance and sensitize cancer cells to stress- or drug-induced apoptosis (Antonyak et al. 2004; Choi et al. 2005; Yuan et al. 2005, 2007; Herman et al. 2006; Kim et al. 2006; Cao et al. 2008; Verma et al. 2008a). It has also been suggested that TG2 overexpression is a general mechanism for the induction of drug resistance independent of multi-drug resistance (Han and Park 1999a). However, one study recently demonstrated that increased TG2 expression conferred drug resistance to some but not all chemotherapeutics in glioma cells, indicating that the induction of TG2 was not a general mechanism of drug resistance (Dyer et al. 2011).

The exact mechanism through which TG2 expression is induced and mediates drug resistance is not completely understood. The involvement of TG2 in many important pathways that regulate several hallmarks of cancer may explain its role in drug resistance (Table 1).

Several studies have reported a straightforward relationship between TG2 expression and doxorubicin drug resistance. Han and colleagues demonstrated that the generation of hydrogen peroxide induced by doxorubicin treatment was one of the key factors in enhancing TG2 expression in lung cancer cells (Han and Park 1999b). Proteomic analysis (Park et al. 2007) and epigenetic profiling (Chekhun et al. 2007) studies of doxorubicin-resistant breast cancer cells confirmed the role of TG2 as a target protein to increase doxorubicin resistance. Another mechanism of TG2 induction involves the activation of the EGF signaling pathway, which may contribute to the oncogenic potential of breast cancer cells by promoting chemoresistance toward doxorubicin and other drugs (Antonyak et al. 2004). Moreover, under stress conditions, TG2 expression can be regulated by the activation of several different pathways as well as by transcription factors, such as HIF-1 or NFκB (Jang et al. 2010a; Mehta et al. 2010), or epigenetic mechanisms (Park et al. 2010b; Dyer et al. 2011).

TG2 overexpression in various cancer cell types is often associated with constitutive activation of NFκB (Verma and Mehta 2007). Moreover, the inhibition of TG2 activity by specific inhibitors can down-regulate NFκB activity (Kim et al. 2006; Cao et al. 2008). Several signaling pathways implicated in cancer likely lead to the activation of NFκB, a family of transcription factors that activates genes responsible for cell proliferation, survival, angiogenesis and metastasis. In many cancers, chemotherapy also induces constitutive activation of NFκB, thereby making the tumor refractory to the treatment. The main regulation of NFκB occurs through association with the inhibitor IκB family of proteins. In response to stimuli, NFκB-bound IκBa is phosphorylated and then degraded by the proteasome, which results in the release of NFκB dimers that translocate into the nucleus, where they bind response elements to activate target genes. The p65 subunit may be further altered by post-translational modifications such as phosphorylation, acetylation or methylation, all of which are important for the regulation of NFκB activity.

| Mechanism                                      | Drug          | Tumor type         | References                                                                 |
|------------------------------------------------|---------------|--------------------|---------------------------------------------------------------------------|
| Activation of survival pathways (NFκB, Bcl2, BclXl, EGF, JNK, ERK, AKT, FAK) | Doxorubicin   | Breast, glioma, NSCLC | (Antonyak et al. 2004; Kim et al. 2006, 2009; Park et al. 2010b; Dyer et al. 2011) |
|                                               | Cisplatin     | Ovarian, NSCLC     | (Cao et al. 2008; Park et al. 2010b)                                       |
|                                               | TRAIL         | NCLC               | (Li et al. 2011)                                                          |
|                                               | Gemcitabine   | Pancreas           | (Verma et al. 2008a)                                                      |
|                                               | Retinoic acid |                   | (Antonyak et al. 2003)                                                    |
|                                               | HDAC-Is       | Breast, head and neck, colon | Carbone and Budillon, unpublished data                                    |
| Inhibition of apoptosis (Bax, DR5, survivin, Bim, Bad, cFLIP) | Doxorubicin   | Breast             | (Park et al. 2009)                                                       |
|                                               | BCNU, Radiation | Glioblastoma      | (Yuan et al. 2005, 2011)                                                  |
|                                               | TRAIL         | NSCLC, renal       | (Frase-Schaper et al. 2010; Jang et al. 2010b)                            |
| Alteration of ECM proteins                    | Doxorubicin   | Breast             | (Herman et al. 2006)                                                      |
|                                               | cisplatin and dacarbazine | Melanoma | (Fok et al. 2006)                                                        |
|                                               | BCNU          | Glioblastoma       | (Yuan et al. 2007)                                                       |
|                                               |               | Pancreas           | (Akar et al. 2007)                                                       |
| Regulation of autophagy                       | Doxorubicin   | Breast, ovarian    | (Shao et al. 2009; Kumar et al. 2010)                                     |
| Induction of EMT                              | Doxorubicin   | Breast             | (Chekhun et al. 2007; Park et al. 2007)                                   |
| Gene regulation                               | Doxorubicin   |                   |                                                                           |
which affect its function and binding to co-activators or repressors. The capability of TG2 to increase NFκB activity has been described in breast cancer cells resistant to doxorubicin (Kim et al. 2006). Interestingly, the induction of TG2-mediated NFκB activity was observed in both EGFR-positive and EGFR-negative breast cancer cells (Kim et al. 2006). The involvement of NFκB in TG2-mediated cisplatin resistance was reported in epithelial ovarian cancer cells, where a cytotoxic synergistic interaction between the TG2 inhibitor KCC009 and cisplatin demonstrated that the enzymatic activity of TG2 was important for modulating NFκB function (Cao et al. 2008). Our group has recently demonstrated that vorinostat, an HDAC inhibitor, induces TG2 expression in cancer cell lines from different tissues of origin and that this induction represents a mechanism of resistance against the anti-tumor effects of vorinostat.1 We have also shown the existence of a vorinostat-induced NFκB-dependent loop mediating TG2 induction and resistance.

TG2, through its functional and structural complexity, contributes to the regulation of NFκB in different ways. TG2 can form a direct complex with NFκB p50/p65 dimers in the cytoplasm and modify its affinity for IkBz (Verma and Mehta 2007). It has also been shown that IkBz is a good substrate for TG2 and that linkage of these proteins can induce the creation of an insoluble cytosolic polymer that is unable to bind and sequester NFκB in the cytosol (Lee et al. 2004). TG2 can also associate with p65 in the nucleus and redirect it to non-canonical targets, including the TG2 gene itself, leading to the formation of a positive feedback loop in resistant cells (Verma and Mehta 2007). Moreover, p65 serves as substrate for TG2 serine–threonine kinase activity and can be phosphorylated by TG2 at Ser536, which is required for transactivation activity (Verma and Mehta 2007).

Recently, Li et al. demonstrated that TG2 mediates tumor necrosis factor-related apoptosis-inducing factor (TRAIL) resistance and cell migration through c-FLIP and MMP-9. They showed EGFR-mediated TG2 expression via JNK and ERK, but not AKT and NFκB, confirming the existence of multiple mechanisms that mediate TG2-induction in resistant cells (Li et al. 2011). Interestingly, the TG2 inhibitor KCC009 reversed resistance to TRAIL through the up-regulation of death receptor 5 (DR5) in lung cancer cells, independent of NFκB and p53 (Frese-Schaper et al. 2010).

Other drug resistance mechanisms may involve the capability of TG2 to promote degradation of the phosphatase PTEN, resulting in the constitutive activation of the FAK/AKT cell survival pathway and resistance to gemcitabine, which can be reversed by knocking down TG2 expression (Verma et al. 2006, 2008b). TG2 overexpression downregulates the susceptibility of doxorubicin-resistant breast cancer cells to drug-induced apoptosis and also decreases the expression of cell survival factors such as Bcl2 and BclXL via NFκB (Kim et al. 2009), but also inhibits accumulation of cytosolic nucleophosmin, an anti-apoptotic protein that binds Bax and decreases its levels (Park et al. 2009). Inhibition of TG2 activity by KCC009 or KCA075 results in the sensitization of glioblastoma cells to (N,N′-bis(2-chloroethyl)-N-nitrosourea, carmustine (BCNU) by changing the levels and activity of pro- and anti-apoptotic proteins, such as Bim, Bad and GSK-3β (Yuan et al. 2005).

In addition to activation of survival pathways or inhibition of apoptosis, TG2 also mediates chemoresistance by regulating ECM proteins. As reported above, TG2 may contribute to doxorubicin resistance in breast cancer cells by promoting interactions between integrins and fibronectin and activating cell survival signaling pathways (Herman et al. 2006). To support this mechanism, it was shown that interference of the interaction between TG2 and fibronectin in the ECM by the TG2 inhibitor KCC009 enhances the sensitivity of glioblastoma cells to BCNU (Yuan et al. 2007). In melanoma cells, TG2 expression promotes integrin-mediated cell survival signaling pathways, resulting in cisplatin and dacarbazine resistance (Fok et al. 2006).

As reported above, TG2 can promote EMT as well as stem cell characteristics. Recent evidence now indicates that tumor cell EMT not only causes increased metastasis, but also contributes to drug resistance. EMT reflects the emergence of chemorefractory cells with stem cell-like features and also seems to play a role in establishing the resistance to molecular anti-cancer compounds such as EGFR targeting agents or anti-VEGF agents (Bruzzese et al. 2011; Carbone et al. 2011). Additionally, TG2-induced EMT may result from the constitutive activation of NFκB, confirming a crucial role for this pathway in TG2-mediated chemoresistance and tumor aggressiveness (Mehta et al. 2010). More debated is the role of the cross-talk between TG2 and a potent inducer of EMT such as TGF/β (Mehta et al. 2010).

Recently, it has also been shown that TG2 may regulate autophagy (Akar et al. 2007; D’Eletto et al. 2009). Autophagy is a homeostatic and catabolic process by which cells consume parts of themselves to survive starvation and stress. Autophagy is also a mechanism of stress tolerance that maintains cell viability and can lead to tumor dormancy, progression and therapeutic resistance. However, in some contexts, excessive or prolonged autophagy can lead to tumor cell death. TG2 catalyzes the final steps in autophagosome formation during autophagy (D’Eletto et al. 2009). However, the induction of TG2 by PKCθ results in the suppression of autophagic cell death in pancreatic

1 Carbone and Budillon, unpublished data.
| Compound                        | Structure | Specificity | IC₅₀ values (in vitro assay) | Mechanism of action                                                                 | Application in experimental disease models |
|--------------------------------|-----------|-------------|-----------------------------|-------------------------------------------------------------------------------------|---------------------------------------------|
| Irreversible inhibitors        |           | Specific    | 1–10 μM                    | Inhibition of catalytic triad                                                         | Cancer: ovarian, glioblastoma, non-small cell lung, melanoma, breast, colon, meningiomas |
| KCC009                         | ![Structure](image1) | Specific    | 0.1–1 mM                   | Disulfide bonding formation                                                          | Neurodegenerative disease                   |
| KCA075                         | ![Structure](image2) | Not specific| 0.01 μM                    | Disulfide bonding formation, competition of GTP-binding site                        | Neurodegenerative disease                   |
| Iodoacetamide                  | ![Structure](image3) | Specific    | 0.005 μM                   | Neurodegenerative disease                                                            |                                             |
| Reversible inhibitors          |           | Specific    | 3 μM                       | Competition of GTP-binding site                                                     | Cancer: small cell lung, ovarian, breast, pancreatic, lymphoma; neurodegenerative disease |
| Thieno[2,3-d]pyrimidin-4-one acylhydrazide (LDN-27219) | ![Structure](image4) | Specific | 0.004 mM                   | Pan-transglutaminase inhibition                                                     | Celiac sprue                                |
| ZM39923                        | ![Structure](image5) | Not specific| 0.015 mM, complete inhibition| Neurodegenerative disease                                                            |                                             |
| ZM449828                       | ![Structure](image6) | Not specific| 0.004 mM                   | Pan-transglutaminase inhibition                                                     | Celiac sprue                                |
| Compound                  | Structure | Specificity  | IC<sub>50</sub> values (in vitro assay) | Mechanism of action                                                                 | Application in experimental disease models |
|--------------------------|-----------|-------------|--------------------------------------|-------------------------------------------------------------------------------------|---------------------------------------------|
| Competitive amino inhibitors | Norleucine | Not specific | 0.018 mM                             | Competitive amine inhibitors                                                        | Celiac sprue                                |
| MDC                      |           | Specific    | Unknown                              | Competitive amine inhibitors                                                        | Cancer: colon, non-small cell lung, melanoma, breast, ovarian, glioblastoma |
| Putrescine               |           | Specific    | Unknown                              | Competitive amine inhibitors                                                        | Cancer: neuroblastoma                        |
| 5-(biotinamido)pentylamine |           | Specific    | Unknown                              | Competitive amine inhibitors                                                        | Cancer: colon, neuroblastoma                |
| Cystamine                |           | Not specific| 0.022 mM                             | Disulfide bonding formation, competition of GTP-binding site, competitive amine inhibitor | Cancer: colon, breast, non-small cell lung, liver, glioblastoma; neurodegenerative disease |
cancer cells that are frequently insensitive to standard chemotherapeutic agents (Akar et al. 2007). It has been suggested that the transamidating activity of TG2 in particular is a key regulator of cross-talk between autophagy and apoptosis (Rossin et al. 2011).

TG2 targeting

Overall, reported data indicate that TG2 can represent a marker for poor patient prognosis and that its expression correlates with resistance to treatment and tumor metastasis in both animal models and human cancers. Therefore, it is increasingly clear that TG2 is a novel putative therapeutic target for the treatment of resistant or advanced tumors. Because increasing evidence has suggested that TG2 is involved in numerous diseases such as inflammation and cancer and those of the central nervous system, many small molecules capable of blocking the activity of this protein have been recently developed.2

The TG2 inhibitors developed thus far can be divided in three classes based on their mechanisms of inhibition; only a few have been used in cancer models, and none have been used in patients (Siegel and Khosla 2007). The most frequently used and best defined for their potential anticancer and those of the central nervous system, many small tumor effects are summarized in Table 2. Irreversible inhibitors such as KCC009 or KCA075 prevent enzyme activity by covalently modifying the enzyme, thereby preventing substrate binding. These inhibitors, as reported in the previous sections, have been used to enhance both in vitro and in vivo chemotherapy in several preclinical cancer models, such as ovarian, non-small cell lung, melanoma, breast and colon cancers as well as glioblastoma and meningioma (Yuan et al. 2005, 2007, 2008, 2011; Cao et al. 2008; Satpathy et al. 2009; Frese-Schaper et al. 2010). Reversible TG2 inhibitors block substrate access to the enzyme active site without covalently modifying the enzyme. The competitive amine inhibitors block TG2 activity by competing with natural amine substrates, such as protein-bound lysine residues, in the transamidation reaction. One such agent that is commonly used to inhibit TG2 activity is monodansylcadaverine (MDC), one of the first compounds used in experimental models. Structural similarity with the lysine side chain allows MDC to be used not only as an amine donor for the fluorescence incorporation assay of TG2 activity, but also as a competitive substrate to inhibit cross-linking of natural substrates (Yuan et al. 2005). Cystamine is not a specific inhibitor, because it can act as an amine competitor, an inducer of TG2 disulfide bonds and a GTP-binding compound. Recent findings suggest that cystamine may be an effective sensitizer of TRAIL-induced apoptosis (Jang et al. 2010b).

On the other hand, Metha et al (2010) suggested that the transamidation activity of TG2 was not involved in the EMT process, chemoresistance or metastasis. These authors suggested alternate approaches to downregulate TG2 expression, such as the application of small interfering RNA (siRNA) oligonucleotides rather than TG2 inhibitors. Indeed, TG2 siRNA was successfully delivered to orthotopically growing pancreatic tumors in nude mice and significantly enhanced the therapeutic efficacy of gemcitabine (Verma et al. 2008a). However, although these latter approaches have been successfully used in preclinical models both in vitro and in vivo, clinical evidence for the effectiveness of this therapeutic approach is modest and several concerns for their application in patients can be raised (Chen and Zhaori 2011).

Conclusions

The role of TG2 in tumors is still controversial because it might promote or suppress apoptosis or tumor growth. Moreover, although we summarized the evidence suggesting that TG2 can be considered a good target to reverse drug resistance, several reports have suggested that transcriptional activation of TG2 might, on the contrary, contribute to the growth inhibitory effect of several anti-tumor agents (Esposito et al. 2003; Palmieri et al. 2007; Lentini et al. 2009). Notably, TG2 induction can play opposite roles for the same chemotherapeutic agent depending on the context. A typical example is retinoic acid (RA), a potent activator of TG2. TG2 was identified as a direct RA target gene having a functional retinoid response element in its promoter (Nagy et al. 1996). TG2 expression was induced by RA in human pancreatic cancer cells, and its inhibition partially reversed the antiproliferative effect of RA (El-Metwally et al. 2005). Moreover, it was demonstrated that induction of TG2 by RA through the PML-RAR signaling pathway induced differentiation of acute promyelocytic leukemia (Benedetti et al. 1996). On the other hand, RA-mediated expression of TG2 also induced increased migration and invasion (Joshi et al. 2006). Other evidence has suggested that TG2 may serve as a survival factor and is induced by RA via a mechanism involving PI3K, which is antagonized by the Ras-ERK pathways (Antonyak et al. 2003). Thus, TG2 functions are dictated by its cellular location, interaction with other proteins and environmental or disease context. Cytosolic TG2 shows only latent transamidating activity due to low Ca2+ inside the cells and is mainly involved in signal transduction pathways, but can be activated and participate in the cellular response to extreme

2 http://www.brenda-enzymes.org/php/result_flat.php4?ecno=2.3.2.13.
stresses such as hypoxia, nutrient deprivation or in response to chemotherapeutic agents.

Interestingly, in addition to the complex protein structure, recent studies have suggested that two structurally distinct TG2 protein isoforms, the full-length (TG2-L) and short-length (TG2-S), form that result from alternative splicing and exert different effects on cell survival and differentiation (Antonyak et al. 2006; Tee et al. 2010). Both isoforms retain transamidation activity, but the short isoform lacks the residual GTP-binding and carboxy-terminal portion for the recognition and binding to phospholipase C. The TG2-L isoform confers a strong survival advantage to cells, whereas TG2-S is pro-apoptotic. Interestingly, the ability of TG2-S to induce cell death is not dependent on transamidation, but rather on its unusual ability to undergo high-order aggregations and consequently to induce inappropriate protein oligomerization, an increasingly common mechanism for inducing cell death (Antonyak et al. 2006). Furthermore, overexpression of TG2-S or of the GTP mutant of TG2-L as well as repression of TG2-L expression or of its transamidase activity induced differentiation in neuroblastoma cells (Tee et al. 2010). Other studies are needed to demonstrate that the controversial role of TG2 we have described could be ascribed to distinct expression of the two isoforms. However, these findings are particularly intriguing and challenging, suggesting the selection of isoform-specific inhibitors from a therapeutic point-of-view.

In conclusion, additional insights into the multifunctional nature of TG2 as well as translational studies on the correlation between TG2 expression, function or location and cancer behavior might help to translate TG2 targeting from the bench to bedside.

Acknowledgments This work was partially supported by a research grant to Alfredo Budillon from the nonprofit “Associazione Italiana per la Ricerca sul Cancro” (AIRC IG 9332). The authors thank Dr. Alessandra Trocino and Mrs. Adele De Caro from the National Cancer Institute of Naples for providing excellent bibliographic service and assistance.

Conflict of interest The authors have no conflicts of interest to declare.

Open Access This article is distributed under the terms of the Creative Commons Attribution Noncommercial License which permits any noncommercial use, distribution, and reproduction in any medium, provided the original author(s) and source are credited.

References

Akar U, Ozpolt B, Mehta K, Fok J, Kondo Y, Lopez-Berestein G (2007) Tissue transglutaminase inhibits autophagy in pancreatic cancer cells. Mol Cancer Res 5:241–249

Akimov SS, Krylov D, Fleischman LF, Belkin AM (2000) Tissue transglutaminase is an integrin-binding adhesion coreceptor for fibronectin. J Cell Biol 148:825–838

Antonyak MA, McNeill CJ, Wakshlag JJ, Boehm JE, Cerione RA (2003) Activation of the Ras-ERK pathway inhibits retinoic acid-induced stimulation of tissue transglutaminase expression in NIH3T3 cells. J Biol Chem 278:15859–15866

Antonyak MA, Miller AM, Jansen JM, Boehm JE, Balkman CE, Wakshlag JJ, Page RL, Cerione RA (2004) Augmentation of tissue transglutaminase expression and activation by epidermal growth factor inhibit doxorubicin-induced apoptosis in human breast cancer cells. J Biol Chem 279:41461–41467

Antonyak MA, Jansen JM, Miller AM, Ly TK, Endo M, Cerione RA (2006) Two isoforms of tissue transglutaminase mediate opposing cellular fates. Proc Natl Acad Sci USA 103:18609–18614

Benedetti L, Grignani F, Sciacchitano BM et al (1996) Retinoid-induced differentiation of acute promyelocytic leukemia involves PML-RARalpha-mediated increase of type II transglutaminase. Blood 87:1939–1950

Boehm JE, Singh U, Combis C, Antonyak MA, Cerione RA (2002) Tissue transglutaminase protects against apoptosis by modifying the tumor suppressor protein p110 Rb. J Biol Chem 277:20127–20130

Bruzese F, Leone A, Rocco M, Carbone C, Piro G, Caraglia M, Di Gennaro E, Budillon A (2011) HDAC inhibitor vorinostat enhances the antitumor effect of gefitinib in squamous cell carcinoma of head and neck by modulating ErbB receptor expression and reverting EMF. J Cell Physiol 226:2378–2390

Cao L, Petrusca DN, Satpathy M, Nakshatri H, Petracek I, Materi D (2008) Tissue transglutaminase protects epithelial ovarian cancer cells from cisplatin-induced apoptosis by promoting cell survival signaling. Carcinogenesis 29:1893–1900

Carbone C, Moccia T, Zhu C, Paradiso G, Budillon A, Chiao PJ, Abbruzzese JL, Melisi D (2011) Anti-VEGF treatment-resistant pancreatic cancers secrete proinflammatory factors that contribute to malignant progression by inducing an EMT cell phenotype. Clin Cancer Res 17:5822–5832

Chau DY, Collighan RJ, Verderio EA, Addy VL, Griffin M (2005) The cellular response to transglutaminase-cross-linked collagen. Biomaterials 26:6518–6529

Chekhun VF, Lukyanova NV, Kovalchuk O, Tryndyak VP, Pogribnya IP (2007) Epigenetic profiling of multidrug-resistant human MCF-7 breast adenocarcinoma cells reveals novel hyper- and hypomethylated targets. Mol Cancer Ther 6:1089–1098

Chen SH, Zhaori G (2011) Potential clinical applications of siRNA technique: benefits and limitations. Eur J Clin Invest 41:221–232

Choi K, Siegel M, Piper JL, Yuan L, Cho E, Strnad P, Omary B, Rich KM, Khosla C (2005) Chemistry and biology of dihydroisoaxazole derivatives: selective inhibitors of human transglutaminase 2. Chem Biol 12:469–475

Collighan RJ, Griffin M (2009) Transglutaminase 2 cross-linking of matrix proteins: biological significance and medical applications. Amino Acids 36:659–670

D’Eletto M, Farrace MG, Falasca L, Reali V, Oliverio S, Melino G, Griffin M, Fimia GM, Piacentini M (2009) Transglutaminase 2 is involved in autophagosome maturation. Autophagy 5:1145–1154

Dyer LM, Schooler KP, Ai L, Klop C, Qui J, Robertson KD, Brown KM, Khosla C (2005) Chemistry and biology of dihydroisoaxazole derivatives: selective inhibitors of human transglutaminase 2. Chem Biol 12:469–475

El-Metwally TH, Hussein MR, Pour PM, Kusznyski CA, Adrian TE (2005) Natural retinoids inhibit proliferation and induce apoptosis in pancreatic cancer cells previously reported to be retinoid resistant. Cancer Biol Ther 4:474–483

Esposito C, Marra M, Giuberti G, D’Alessandro AM, Porta R, Cozzolino A, Caraglia M, Abbruzzese A (2003) Ubiquitination
of tissue transglutaminase is modulated by interferon alpha in human lung cancer cells. Biochem J 370:205–212

Fisher M, Jones RA, Huang L, Haylor JL, El Nahas M, Griffin M, Johnson TS (2009) Modulation of tissue transglutaminase in tubular epithelial cells alters extracellular matrix levels: a potential mechanism of tissue scarring. Matrix Biol 28:20–31

Fok JY, Ekmcikcioglu S, Mehta K (2006) Implications of tissue transglutaminase expression in malignant melanoma. Mol Cancer Ther 5:1493–1503

Frese-Schaper M, Schardt JA, Sakai T, Carboni GL, Schmid RA, Frese S (2010) Inhibition of tissue transglutaminase sensitizes TRAIL-resistant lung cancer cells through upregulation of death receptor 5. FEBS Lett 584:2867–2871

Grigoriev MY, Suspitsin EN, Togo AV et al (2001) Tissue transglutaminase expression in breast carcinomas. J Exp Clin Cancer Res 20:265–268

Han J, Park SC (1999a) Reduction of transglutaminase 2 expression is associated with an induction of drug sensitivity in the PC-14 human lung cancer cell line. J Cancer Res Clin Oncol 125:89–95

Han J, Park SC (1999b) Hydrogen peroxide mediates doxorubicin-induced transglutaminase 2 expression in PC-14 human lung cancer cell line. Exp Mol Med 31:83–88

Herman JF, Mangala LS, Mehta K (2006) Implications of increased tissue transglutaminase (TG2) expression in drug-resistant breast cancer (MCF-7) cells. Oncogene 25:3049–3058

Iacobuzio-Donahue CA, Ashfaq R, Maitra A et al (2003) Highly expressed genes in pancreatic ductal adenocarcinomas: a comprehensive characterization and comparison of the transcription profiles obtained from three major technologies. Cancer Res 63:8614–8622

Jang KY, Jeon JH, Cho SY et al (2010a) Transglutaminase 2 suppresses apoptosis by modulating caspase 3 and NF-kappaB activity in hypoxic tumor cells. Oncogene 29:356–367

Jang JH, Park JS, Lee TJ, Kwon TK (2010b) Transglutaminase 2 expression levels regulate sensitivity to cystamine plus TRAIL-mediated apoptosis. Cancer Lett 287:224–230

Joshi S, Guleria R, Pan J, DiPette D, Singh US (2006) Retinoic acid receptors and tissue-transglutaminase mediate short-term effect of retinoic acid on migration and invasion of neuroblastoma SH-SY5Y cells. Oncogene 25:240–247

Kim DS, Park SS, Nam BH, Kim IH, Kim SY (2006) Reversal of drug resistance in breast cancer cells by transglutaminase 2 inhibition and nuclear factor-kappaB inactivation. Cancer Res 66:10936–10943

Kim DS, Park KS, Kim SY (2009) Silencing of TGase 2 sensitizes breast cancer cells to apoptosis by regulation of survival factors. Front Biosci 14:2514–2521

Kumar A, Xu J, Brady S, Gao H, Yu D, Reuben J, Mehta K (2010) Tissue transglutaminase promotes drug resistance and invasion by inducing mesenchymal transition in mammary epithelial cells. PLoS One 5:e13390

Kumar A, Gao H, Xu J, Reuben J, Yu D, Mehta K (2011) Evidence that aberrant expression of tissue transglutaminase promotes stem cell characteristics in mammary epithelial cells. PLoS One 6:e20701

Lee J, Kim YS, Choi DH, Bang MS, Han TR, Joo TH, Kim SY (2004) Transglutaminase 2 induces nuclear factor-kappaB activation via a novel pathway in BV-2 microglia. J Biol Chem 279:53725–53735

Lemini A, Provenzano B, Tabolacci C, Beninati S (2009) Protein-polymine conjugates by transglutaminase 2 as potential markers for antineoplastic screening of natural compounds. Amino Acids 36:701–708

Li Z, Xu X, Bai L, Chen W, Lin Y (2011) Epidermal growth factor receptor-mediated tissue transglutaminase overexpression couples acquired tumor necrosis factor-related apoptosis-inducing ligand resistance and migration through c-FLIP and MMP-9 proteins in lung cancer cells. J Biol Chem 286:21164–21172

Mangala LS, Fok JY, Zorrilla-Calancha IR, Verma A, Mehta K (2007) Tissue transglutaminase expression promotes cell attachment, invasion and survival in breast cancer cells. Oncogene 26:2459–2470

Mann AP, Verma A, Sethi G et al (2006) Overexpression of tissue transglutaminase leads to constitutive activation of nuclear factor-kappaB in cancer cells: delineation of a novel pathway. Cancer Res 66:8788–8795

Martinet N, Bonnard L, Regnault V, Picard E, Burke L, Siat J, Grosdidier G, Martinet Y, Vignaud JM (2003) In vivo transglutaminase type 1 expression in normal lung, preinvasive bronchial lesions, and lung cancer. Am J Respir Cell Mol Biol 28:428–435

Mehta K, Fok J, Miller FR, Koul D, Sahin AA (2004) Prognostic significance of tissue transglutaminase in drug resistant and metastatic breast cancer. Clin Cancer Res 10:8068–8076

Mehta K, Fok JY, Mangala LS (2006) Tissue transglutaminase: from biological glue to cell survival cues. Front Biosci 11:173–185

Mehta K, Kumar A, Kim HI (2010) Transglutaminase 2: a multi-tasking protein in the complex circuitry of inflammation and cancer. Biochem Pharmacol 80:1921–1929

Miyoshi N, Ishii H, Mimori K, Tanaka F, Hitora T, Tei M, Sekimoto M, Doki Y, Mori M (2010) TGTM2 is a novel marker for prognosis and therapeutic target in colorectal cancer. Ann Surg Oncol 17:967–972

Nagy L, Saydk M, Shipley N et al (1996) Identification and characterization of a versatile retinoic acid response element (retinoic acid receptor response element-retinoid X receptor response element) in the mouse tissue transglutaminase gene promoter. J Biol Chem 271:4355–4365

Palmieri G, Montella L, Aiello C et al (2007) Somatostatin analogues, a series of tissue transglutaminase inducers, as a new tool for therapy of mesenchymal tumors of the gastrointestinal tract. Amino Acids 32:395–400

Park SS, Kim DS, Park KS, Song HJ, Kim SY (2007) Proteomic analysis of high-molecular-weight protein polymers in a doxorubicin-resistant breast-cancer cell line. Proteomics Clin Appl 1:555–560

Park KS, Han BG, Lee KH et al (2009) Depletion of nucleophosmin via transglutaminase 2 cross-linking increases drug resistance in cancer cells. Cancer Lett 274:201–207

Park D, Choi SS, Ha KS (2010a) Transglutaminase 2: a multifunctional protein in multiple subcellular compartments. Amino Acids 39:619–631

Park KS, Kim HK, Lee JH, Choi YB, Park SY, Yang SH, Kim SY, Hong KM (2010b) Transglutaminase 2 as a cisplatin resistance marker in non-small cell lung cancer. J Cancer Res Clin Oncol 136:493–502

Rossin F, D’Eletto M, Macdonald D, Farrace MG, Picentini M (2011) TG2 transamidating activity acts as a rheostat controlling the interplay between apoptosis and autophagy. Amino Acids

Satpathy M, Cao L, Pincheira R, Emerson R, Bigsby R, Nakshatri H, Matei D (2007) Enhanced peritoneal ovarian tumor dissemination by tissue transglutaminase. Cancer Res 67:7194–7202

Satpathy M, Shao M, Emerson R, Donner DB, Matei D (2009) Tissue transglutaminase regulates matrix metalloproteinase-2 in ovarian cancer by modulating cAMP-response element-binding protein activity. J Biol Chem 284:15390–15399

Shao M, Cao L, Shen C, Satpathy M, Chelliadurai B, Bigsby RM, Nakshatri H, Matei D (2009) Epithelial-to-mesenchymal transition and ovarian tumor progression induced by tissue transglutaminase. Cancer Res 69:9192–9201

Siegel M, Khosla C (2007) Transglutaminase 2 inhibitors and their therapeutic role in disease states. Pharmacol Ther 115:232–245

Springer
Tee AE, Marshall GM, Liu PY, Xu N, Haber M, Norris MD, Ismaa SE, Liu T (2010) Opposing effects of two tissue transglutaminase protein isoforms in neuroblastoma cell differentiation. J Biol Chem 285:3561–3567
Verma A, Mehta K (2007) Transglutaminase-mediated activation of nuclear transcription factor-kappaB in cancer cells: a new therapeutic opportunity. Curr Cancer Drug Targets 7:559–565
Verma A, Wang H, Manavathi B, Fok JY, Mann AP, Kumar R, Mehta K (2006) Increased expression of tissue transglutaminase in pancreatic ductal adenocarcinoma and its implications in drug resistance and metastasis. Cancer Res 66:10525–10533
Verma A, Guha S, Diagaradjane P et al (2008a) Therapeutic significance of elevated tissue transglutaminase expression in pancreatic cancer. Clin Cancer Res 14:2476–2483
Verma A, Guha S, Wang H, Fok JY, Koul D, Abbrazzese J, Mehta K (2008b) Tissue transglutaminase regulates focal adhesion kinase/AKT activation by modulating PTEN expression in pancreatic cancer cells. Clin Cancer Res 14:1997–2005
Yamaguchi H, Wang HG (2006) Tissue transglutaminase serves as an inhibitor of apoptosis by cross-linking caspase 3 in thapsigargin-treated cells. Mol Cell Biol 26:569–579
Yuan L, Choi K, Khosla C, Zheng X, Higashikubo R, Chicoine MR, Rich KM (2005) Tissue transglutaminase 2 inhibition promotes cell death and chemosensitivity in glioblastomas. Mol Cancer Ther 4:1293–1302
Yuan L, Siegel M, Choi K, Khosla C, Miller CR, Jackson EN, Ptwnica-Worms D, Rich KM (2007) Transglutaminase 2 inhibitor, KCC009, disrupts fibronectin assembly in the extracellular matrix and sensitizes orthotopic glioblastomas to chemotherapy. Oncogene 26:2563–2573
Yuan L, Behdad A, Siegel M, Khosla C, Higashikubo R, Rich KM (2008) Tissue transglutaminase 2 expression in meningiomas. J Neurooncol 90:125–132
Yuan L, Holmes TC, Watts RE, Khosla C, Broekelmann TJ, Mechem R, Zheng H, Izaguirre EW, Rich KM (2011) Novel chemosensitizing agent, ERW1227B, impairs cellular motility and enhances cell death in glioblastomas. J Neurooncol 103:207–219
Zhang R, Tremblay TL, McDermid A, Thibault P, Stanimirovic D (2003) Identification of differentially expressed proteins in human glioblastoma cell lines and tumors. Glia 42:194–208